These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30907010)

  • 1. Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network.
    Mertes PM; Tacquard C; Andreu G; Kientz D; Gross S; Malard L; Drouet C; Carlier M; Gachet C; Sandid I; Boudjedir K
    Transfusion; 2020 Mar; 60(3):507-512. PubMed ID: 30907010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity transfusion reactions to fresh frozen plasma: a retrospective analysis of the French hemovigilance network.
    Tacquard C; Andreu G; Meyer N; Carlier M; Py JY; Drouet C; Bienvenu J; Mertes PM; Boudjedir K
    Transfus Med Rev; 2022 Apr; 36(2):77-81. PubMed ID: 35501216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.
    Pitman JP; Payrat JM; Park MS; Liu K; Corash L; Benjamin RJ
    Transfusion; 2023 Apr; 63(4):711-723. PubMed ID: 36802055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
    Richard P; Pouchol E; Sandid I; Aoustin L; Lefort C; Chartois AG; Baima A; Malard L; Bacquet C; Ferrera-Tourenc V; Gallian P; Laperche S; Bliem C; Morel P; Tiberghien P
    Vox Sang; 2024 Mar; 119(3):212-218. PubMed ID: 38152857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion reactions after transfusion of platelets stored in PAS-B, PAS-C, or plasma: a nationwide comparison.
    van Hout FMA; van der Meer PF; Wiersum-Osselton JC; Middelburg RA; Schipperus MR; van der Bom JG; Kerkhoffs JL
    Transfusion; 2018 Apr; 58(4):1021-1027. PubMed ID: 29405304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems.
    Benjamin RJ; Braschler T; Weingand T; Corash LM
    Transfusion; 2017 Dec; 57(12):2946-2957. PubMed ID: 28840603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Transfusion-Related Acute Lung Injury and Possible Transfusion-Related Acute Lung Injury Reported to the French Hemovigilance Network From 2007 to 2013.
    Andreu G; Boudjedir K; Muller JY; Pouchol E; Ozier Y; Fevre G; Gautreau C; Quaranta JF; Drouet C; Rieux C; Mertes PM; Clavier B; Carlier M; Sandid I
    Transfus Med Rev; 2018 Jan; 32(1):16-27. PubMed ID: 28864336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions.
    Kobayashi J; Yanagisawa R; Ono T; Tatsuzawa Y; Tokutake Y; Kubota N; Hidaka E; Sakashita K; Kojima S; Shimodaira S; Nakamura T
    Vox Sang; 2018 Feb; 113(2):128-135. PubMed ID: 29067694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
    Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
    Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of platelet additive solution-E stored platelet concentrates.
    Spelmink SE; Jager ST; van de Watering L; van der Meer PF; van Gammeren AJ; Wiersum-Osselton JC; Klei TRL; Kerkhoffs JH;
    Transfusion; 2023 Dec; 63(12):2273-2280. PubMed ID: 37909172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study.
    Ikebe E; Matsuoka S; Tanaka A; Yonemura Y; Fujii Y; Ohsaka A; Okazaki H; Kitazawa J; Ohtani S; Nakayama T; Momose SY; Miwa I; Taira R; Toyota K; Kino S; Kato H; Hamaguchi I
    Transfus Apher Sci; 2019 Apr; 58(2):162-168. PubMed ID: 30670326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
    Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
    Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
    Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
    Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.
    de Wildt-Eggen J; Nauta S; Schrijver JG; van Marwijk Kooy M; Bins M; van Prooijen HC
    Transfusion; 2000 Apr; 40(4):398-403. PubMed ID: 10773049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions].
    Rebibo D; Simonet M; Hauser L
    Transfus Clin Biol; 2008 Nov; 15(5):289-93. PubMed ID: 18930424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.